Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/28/2022* -- Results Q3 2022 -- 3.57 --
10/28/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
07/29/2022 09:00 EST Earnings Call Q2 2022 -- -- --
07/29/2022 -- Results Q2 2022 3.37 3.31 1.83%
04/29/2022 -- Results Q1 2022 3.16 3.14 0.56%
04/29/2022 09:00 EST Earnings Call Q1 2022 -- -- --
02/02/2022 -- Results Q4 2021 3.31 3.28 0.84%
02/02/2022 09:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/28/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/29/2022
Beat/Miss Upgrade
Return Since -1.06%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 29, 2022
Next Ex-Dividend Date Oct. 13, 2022
Last Ex-Dividend Date Jul. 14, 2022

Dividends

Dividend Per Share (TTM) 5.42
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.722
Yield to Sector 2.167
Yield to Industry 1.081
Last Dividend Amt. 1.41
Dividend Frequency Quarterly
Last Ex-Dividend Date Jul. 14, 2022
Yield (TTM) 3.89%
Forward Yield 3.97%
Payout Ratio 76.46%
Cash Payout Ratio 43.50%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-6.46%
9.88%
60.13%
-0.98%
1.50%
27.61%
32.40%
7.92%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
-2.73%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
20.71%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
17.11%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-22.94%
As of October 04, 2022.

Profile

Edit
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 29, 2022
Next Ex-Dividend Date Oct. 13, 2022
Last Ex-Dividend Date Jul. 14, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CMLFX 2.289B USD 2.78%
CIRFX 2.006B USD 2.00%
VYM 1.009B USD 1.74%
IWF 818.12M USD 1.46%
VIVAX 2.079B USD 1.45%
VTV 2.079B USD 1.45%
IVV 2.244B USD 0.82%
FXAIX 2.723B USD 0.73%
VFINX 5.342B USD 0.71%
VOO 5.342B USD 0.71%
VTSMX 7.048B USD 0.60%
VTI 7.048B USD 0.60%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ABBV Tweets